Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)
A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel- Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects With Intermittent Claudication (IC)
Sponsor: Pluristem Ltd.
Listed as NCT01679990, this PHASE2 trial focuses on Intermittent Claudication and Peripheral Artery Disease and remains completed. Sponsored by Pluristem Ltd., it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Feb 2019 — Mar 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pluristem Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .